Monte Rosa Therapeutics Shares Surge 45.2% After Phase 1 Data Release

Written by Emily J. Thompson, Senior Investment Analyst

ERAS+10.73%

GLUE+0.29%

LLY-0.36%

Source: Benzinga

Updated: Jan 07 2026

0mins

Source: Benzinga

Stock Surge: Monte Rosa Therapeutics Inc (NASDAQ:GLUE) shares soared 45.2% to $23.25 after announcing interim data from its Phase 1 clinical study evaluating MRT-8102, indicating strong market confidence in its research progress and potentially attracting more investor interest.
Acquisition Rumors: Ventyx Biosciences Inc (NASDAQ:VTYX) saw a 37.5% increase to $13.82 following reports that Eli Lilly & Co (NYSE:LLY) is in advanced talks to acquire the company for over $1 billion, which may further drive market interest in biotech stocks.
Analyst Rating: Erasca Inc (NASDAQ:ERAS) rose 17.1% to $4.25 after Piper Sandler analyst Kelsey Goodwin initiated coverage with an Overweight rating and a price target of $5, reflecting optimism about its future growth potential.
Market Dynamics: The overall market was mixed, with the Dow Jones index falling around 0.2%, yet several biotech stocks performed strongly, reflecting ongoing investor interest and confidence in the sector, which may signal future investment opportunities.

ERAS

$8.31+Infinity%1D

Analyst Views on ERAS

Wall Street analysts forecast ERAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERAS is 4.50 USD with a low forecast of 1.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Analyst Rating

3 Buy

0 Hold

1 Sell

Moderate Buy

Current: 7.505

Low

1.00

Averages

4.50

High

6.00

Current: 7.505

Low

1.00

Averages

4.50

High

6.00

Morgan Stanley

Equal Weight

maintain

$2 -> $4

Al Analysis

2026-01-08

Reason

Morgan Stanley

Price Target

$2 -> $4

Al Analysis

2026-01-08

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Erasca to $4 from $2 and keeps an Equal Weight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Piper Sandler

Overweight

initiated

2026-01-07

Reason

Piper Sandler

Price Target

2026-01-07

initiated

Overweight

Reason

Piper Sandler initiated coverage of Erasca with an Overweight rating and $5 price target. The company is is advancing a "potentially differentiated" RAS-targeted pipeline including a pan-RAS molecular glue, and a pan- KRAS inhibitor, the analyst tells investors in a research note. The firm says preclinical data suggests the potential for superior RAS inhibition and anti-tumor activity virus Revolution Medicines' daraxonrasib.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ERAS

Unlock Now

BofA

Underperform

maintain

$1 -> $2

2026-01-06

Reason

BofA

Price Target

$1 -> $2

2026-01-06

maintain

Underperform

Reason

BofA raised the firm's price target on Erasca to $2 from $1 and keeps an Underperform rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Mizuho

Outperform

upgrade

$4 -> $5

2025-12-09

Reason

Mizuho

Price Target

$4 -> $5

2025-12-09

upgrade

Outperform

Reason

Mizuho raised the firm's price target on Erasca to $5 from $4 and keeps an Outperform rating on the shares. The firm is "increasingly encouraged and constructive" on the RAS space and is bullish on Erasca ahead of its first U.S. Phase 1 clinical data for its two lead assets, ERAS-0015 and ERAS-4001. Mizuho sees large addressable markets for both candidates and notes that data is expected in 2026. The analyst sees an attractive risk/reward at current share levels.

About ERAS

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.